Trends of antifungal use based on sales data in Japan from 2006 to 2015
Open accessAbstract
The detailed epidemiology of invasive mycoses and superficial mycoses has not been clarified in Japan. In addition, treatment options have increased because of novel antifungals and/or guidelines for fungal infection. In the present study, we aimed to clarify the trends of antifungal use in Japan from 2006 to 2015 based on sales data to serve as an alternative indicator of fungal infection trends. We found that the total antifungal use decreased over time (r = −0.057, Pfor trend < 0.0001). Oral and parenteral use significantly decreased by 44.1% (r = −0.056, Pfor trend < 0.0001) and 27.1% (r = −0.0012, Pfor trend = 0.00061), respectively. The trend of antifungal use for superficial mycoses significantly decreased by 49.8% (r = −0.061, Pfor trend < 0.0001). However, the trend of antifungal use for invasive mycoses was significantly increased by 19.9% (r = 0.0032, Pfor trend = 0.00045). In Japan, the increase in the number of immunocompromised patients might be associated with the increase in the frequency of antifungal use for invasive mycoses. This is the first study to clarify the trends of antifungal use in Japan. Further research is needed to establish a continuous surveillance system to compare fungal infections between Japan and the world.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Japan, micafungin is generally prescribed for candidiasis.
“In Japan, MCFG is generally prescribed for candidiasis.25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463 · see citing works
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,408 · see citing works
Parczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656 · see citing works
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231 · see citing works
Breakthrough Trichosporonosis in Patients with Hematologic Malignancies Receiving Micafungin
Matsue, K., Uryu, H., Koseki, M., Asada, N., & Takeuchi, M. (2006) · Clinical Infectious Diseases · doi:10.1086/500323 · Cited by 156 · see citing works
Cornely, O. A., Gachot, B., Akan, H., Bassetti, M., Uzun, Ö., Kibbler, C. C., Marchetti, O., de Burghgraeve, P., Ramadan, S., Pylkkänen, L., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ293 · Cited by 142 · see citing works
Global trends in lifespan inequality: 1950-2015
Permanyer, I., & Scholl, N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215742 · Cited by 99 · see citing works
Executive Summary of Japanese Domestic Guidelines for Management of Deep-seated Mycosis 2014
Kohno, S., Tamura, K., Niki, Y., Izumikawa, K., Oka, S., Ogawa, K., Kadota, J., Kamei, K., Kanda, Y., Kiuchi, T., et al. (2016) · Medical Mycology Journal · doi:10.3314/mmj.16-00010 · Cited by 47 · see citing works
Predicting the emergence of resistance to antifungal drugs
Cowen, L. E. (2001) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2001.tb10853.x · Cited by 36 · see citing works
Adriaenssens, N., Coenen, S., Muller, A., Vankerckhoven, V., Goossens, H., & on behalf of the ESAC Project Group (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq023 · Cited by 32 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Permanyer I, Scholl N. Global trends in lifespan inequality: 1950-2015. PLOS ONE, 14, e0215742 (2019). · DOI
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of inci- dence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 68, 394-424 (2018). · DOI · Paper page
- Kohno S, Tamura K, Niki Y, et al. Executive summary of Japanese domestic guidelines for management of deep-seated mycosis 2014. Med. Mycol. J., 57, E117-E163 (2016). · DOI
- Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J. Antimicrob. Chemother., 65, 769-774 (2010). · DOI
Cited by
Sorted by citations
Kajihara, T., Yahara, K., Nagi, M., Kitamura, N., Hirabayashi, A., Hosaka, Y., Abe, M., Miyazaki, Y., & Sugai, M. (2022) · Medical Mycology · doi:10.1093/mmy/myac071 · Cited by 29 · see citing works
Goto, R., Inose, R., Kusama, Y., Kawabe, A., Ishii, S., Ebisui, A., Ishikane, M., Yagi, T., Ohmagari, N., & Muraki, Y. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00605 · Cited by 14 · see citing works
Sakamoto, Y., Kawabe, K., Suzuki, T., Sano, K., Ide, K., Nishigaki, T., Enoki, Y., Taguchi, K., Koike, H., Kato, H., et al. (2021) · Journal of Fungi · doi:10.3390/jof7080596 · Cited by 16 · see citing works
Yang, X., Pei, Z., Hu, R., Zhang, Z., Lou, Z., & Sun, X. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00246 · Cited by 11 · see citing works
A Strategy for Hospital Pharmacists to Control Antimicrobial Resistance (AMR) in Japan
Hamada, Y., Ebihara, F., & Kikuchi, K. (2021) · Antibiotics · doi:10.3390/antibiotics10111284 · Cited by 10 · see citing works
Mita, Y., Inose, R., Goto, R., Kusama, Y., Koizumi, R., Yamasaki, D., Ishikane, M., Tanabe, M., Ohmagari, N., & Muraki, Y. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.02.009 · Cited by 8 · see citing works
Nakanishi, T., Inose, R., Kusama, Y., Ishikane, M., Kajihara, T., Yahara, K., Sugai, M., Ohge, H., Ohmagari, N., & Muraki, Y. (2021) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2021.450 · Cited by 7 · see citing works
Muraki, Y., Koizumi, R., Kusama, Y., Inose, R., Ishikane, M., & Ohmagari, N. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00461 · Cited by 4 · see citing works
Trends in Antipseudomonal Agent Use Based on the 2006 to 2015 Sales Data in Japan
Ebisui, A., Inose, R., Kusama, Y., Koizumi, R., Kawabe, A., Ishii, S., Goto, R., Ishikane, M., Yagi, T., Ohmagari, N., et al. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00004 · Cited by 4 · see citing works
- Authors
- Kawabe, A., Muraki, Y., Inose, R., Kusama, Y., Goto, R., Ebisui, A., Ishii, S., Ishikane, M., Ohge, H., & Ohmagari, N.
- Affiliations
- Kyoto Pharmaceutical University (JP)
- National Center for Global Health and Medicine (JP)
- Hiroshima University Hospital (JP)
- ORCID
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2020-08-01
- Volume
- 43
- Issue
- 8
- Pages
- 1248-1252
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W3046496778
- Cited by
- 9
- References
- 12
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 6 · 2020: 1
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Biological and Pharmaceutical Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare (19HA1004)
- Japan Society for the Promotion of Science (18K09957)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
- Keywords
- antifungal agents, sales data, invasive fungal infections, superficial fungal infections, oral antifungal agents, immunocompromised patients, fungal infection surveillance, Japan
- MeSH terms
- Antifungal Agents, Commerce, Drug Utilization, Humans, Japan, Mycoses, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
